Clinical Trials for COVID-19

148 covid-19 trials indexed, 47 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding COVID-19

COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, which belongs to the coronavirus family. This virus primarily targets the respiratory system, entering cells through receptors in the lungs and sometimes other organs. The infection can range from mild to severe, and it spreads mainly through respiratory droplets when an infected person coughs or sneezes. Diagnosis typically involves detecting viral RNA using a polymerase chain reaction (PCR) test from nasal or throat swabs. Rapid antigen tests are also common for quicker results, although they are less sensitive than PCR tests.

Common symptoms of COVID-19 include fever, cough, fatigue, and loss of taste or smell. Some patients experience difficulty breathing, muscle aches, or sore throat. Symptoms usually appear within two to 14 days after exposure. COVID-19 can affect people of all ages, but older adults and those with underlying health conditions such as diabetes, heart disease, or weakened immune systems are at higher risk for severe illness. Children often have milder symptoms but can still spread the virus. Risk factors also include close contact with infected individuals and living in crowded settings.

The medical and social impact of COVID-19 is significant worldwide. Since the pandemic began, millions have been infected, leading to over 6 million deaths globally as of early 2024. The disease has strained healthcare systems, caused economic disruptions, and altered daily life for many. For example, hospitalizations due to COVID-19 reached peaks that overwhelmed intensive care units in several countries. Understanding and managing COVID-19 remains a priority due to its ability to spread rapidly and cause severe health outcomes in vulnerable populations.

The COVID-19 Treatment Landscape

The first-line standard of care for COVID-19 depends on the severity of the illness. For mild cases, treatment usually involves supportive care such as rest, hydration, and fever management with over-the-counter medications like acetaminophen. Patients with moderate to severe disease often require hospitalization, where oxygen therapy is commonly administered to maintain adequate blood oxygen levels. In some cases, antiviral medications may be started early to reduce viral replication. The approach to treatment is often tiered based on symptoms and risk factors, with more aggressive interventions reserved for those at higher risk of complications.

Second- and third-line treatment options include various drug classes. Antiviral drugs such as remdesivir have been used to target the virus directly. Corticosteroids like dexamethasone help reduce inflammation in patients with severe respiratory symptoms. Other treatments may include monoclonal antibodies designed to neutralize the virus, although their use depends on the circulating variants. Immunomodulators and anticoagulants are also considered to manage complications such as excessive immune response and blood clots. These therapies are generally reserved for hospitalized patients or those with worsening symptoms.

Despite available treatments, gaps remain in managing COVID-19 effectively. Some patient subgroups, including immunocompromised individuals, may respond poorly to standard therapies. Resistance to antiviral drugs is a concern as the virus mutates over time. Side effects from medications, such as steroid-induced hyperglycemia or drug interactions, add to the treatment burden. Research continues to focus on finding safer, more effective therapies and understanding how to tailor treatments to different populations. Efforts also include developing oral antivirals and improving strategies to prevent long-term complications.

Why Clinical Trials Matter for COVID-19

Clinical trials offer patients the opportunity to access new treatments that are not yet widely available. These studies often provide closer health monitoring and contribute valuable information to medical science. As of now, there are 148 COVID-19 clinical trials indexed on ClinicalTrials.gov, with 47 currently recruiting participants. Joining a trial can help advance understanding of which therapies work best and for whom. This is especially important as the virus continues to evolve and new variants emerge.

Participating in clinical trials also involves risks. The effectiveness of the treatment being tested is not guaranteed, and some participants may receive a placebo instead of the active drug. Additional clinic visits and tests might be required, which can be inconvenient or stressful. Side effects are possible and may be unknown at the start of the study. It is important for patients to weigh these risks against the potential benefits and discuss them thoroughly with their healthcare providers before enrolling.

The sponsors of COVID-19 clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in designing, funding, and conducting studies. ClinicalTrials.gov serves as a central registry where these trials are listed, providing transparency and easy access to information for patients and doctors. This registry helps ensure that trials meet ethical standards and allows people to find studies that might be suitable for their needs.

What to Look for in a COVID-19 Clinical Trial

Clinical trials are divided into phases 1 through 4, each serving a different purpose. Phase 1 trials test safety and dosage in a small group of participants. Phase 2 trials focus on effectiveness and side effects with more patients. Phase 3 trials compare the new treatment to current standards in large groups. Phase 4 happens after approval to monitor long-term effects. For COVID-19, many trials do not specify a phase (30 trials). Phase 2 trials are the most common with 22 studies, followed by 15 in Phase 1 and 14 in Phase 3.

When joining a COVID-19 trial, inclusion criteria are important to understand. These criteria often include specific age ranges, such as adults over 18 or older adults. Some trials require participants to have had COVID-19 for a certain number of days or to be in a specific stage of illness. Biomarkers or lab tests may be used to confirm infection or immune response. Prior treatments, like antiviral drugs or steroids, can also affect eligibility. These rules help researchers study the treatment in a consistent group of patients.

Exclusion criteria are just as important and often focus on safety. People with certain health conditions, such as severe heart or liver problems, may be excluded. This is because these conditions can increase the risk of side effects or interfere with the study results. Some trials exclude participants who take medications that might interact with the study drug. Safety thresholds, like low blood pressure or kidney function, are also checked. These rules protect participants and ensure reliable data.

From a patient’s point of view, practical factors matter a lot. Trial length can range from a few weeks to several months. Visit schedules vary and may require frequent trips to the study site for tests or treatments. Some trials cover travel costs, but others do not. Before joining, ask the research team about the expected time commitment and any costs involved. Other key questions include: What are the possible risks and benefits? How will my privacy be protected? What happens if I want to leave the trial early? Who can I contact with questions during the study?

Primary Sources and Further Reading

For more detailed information about COVID-19 clinical trials and related health topics, it is helpful to consult trusted sources. These websites provide up-to-date guidance, safety information, and access to trial registries. They can support patients and caregivers in making informed decisions about participation.

Latest Research and Emerging Treatments for COVID-19 (2026)

Current covid-19 research includes several Phase 3 trials testing new drugs and vaccines to improve prevention and treatment. One study is exploring variant-adapted RNA vaccines for children aged 6 months to 12 years. These vaccines, like the bivalent BNT162b2 (original/Omicron BA.4/BA.5), aim to boost the immune response against newer virus variants. This could help protect younger children better as the virus changes over time (NCT05543616). Another study focuses on adults aged 50 to 64, testing the BNT162b2 vaccine to see how well it prevents infection compared to a placebo (NCT07300839). These vaccines work by teaching the immune system to recognize and fight the virus, potentially reducing the risk of severe illness.

For patients at high risk of severe COVID-19, new drugs are also being tested. Molnupiravir is an oral antiviral medicine studied to stop the virus from multiplying inside the body. By reducing viral replication, molnupiravir may lower the chances of hospitalization and death in vulnerable patients (NCT06667700). Another approach uses monoclonal antibodies like VYD2311, which are designed to block the virus from entering human cells. This study involves monthly injections for adults and adolescents 12 years and older and aims to prevent infection before it starts (NCT07298434).

Additional research on vaccines like Novavax’s NVX-CoV2373 looks at safety and immune response in adults aged 18 to 49. These studies help ensure a steady supply of effective vaccines and support ongoing protection against COVID-19 (NCT05463068). For patients and caregivers, these new drugs for covid-19 and vaccine options could mean more tailored protection and treatments. They may reduce the risk of severe disease, hospital stays, and improve recovery chances as the virus continues to evolve. Keeping up with covid-19 new treatment 2026 research provides hope for better management of the illness in different age groups and risk levels.

Frequently asked questions about COVID-19 trials

How do I find COVID-19 clinical trials?

The authoritative source for COVID-19 clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 148 covid-19 studies are currently indexed. You can search by entering "covid-19" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new covid-19 trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most COVID-19 trials in?

Across the 148 covid-19 trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many COVID-19 clinical trials are currently recruiting?

As of the latest scan, 47 covid-19 trials have a "Recruiting" status on ClinicalTrials.gov, out of 148 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting covid-19 trial matches their tracked condition.

Stay informed about covid-19 research

Get a weekly briefing with the trials that matter most.

Start monitoring covid-19 trials